We are live on ! Find out more
PLXP

PLx Pharma Inc. Common Stock

Delisted

PLXP was delisted on the 12th of April, 2023.

63 hedge funds and large institutions have $184M invested in PLx Pharma Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

333% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 6

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

59% more capital invested

Capital invested by funds: $116M → $184M (+$68M)

37% more funds holding

Funds holding: 4663 (+17)

23% more call options, than puts

Call options by funds: $7.56M | Put options by funds: $6.14M

Holders
63
Holders Change
+17
Holders Change %
+36.96%
% of All Funds
1.1%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
22
Increased
26
Reduced
6
Closed
5
Calls
$7.56M
Puts
$6.14M
Net Calls
+$1.42M
Net Calls Change
+$3.46M

PLXP Hedge Fund Activity: Q3 2021 in Review

63 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q3 2021, worth a combined $184M — up 59% from $116M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PLXP positions and 5 closed out — a net gain of 17 holders — while 26 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $3.45M. The largest seller was Marshall Wace, cutting an estimated $6.25M.

  • 63 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q3 2021, up from 46 in Q2 2021.
  • Funds reported $184M of PLx Pharma Inc. Common Stock stock for Q3 2021, up 59% quarter-over-quarter.
  • 22 funds opened new PLx Pharma Inc. Common Stock positions in Q3 2021 and 5 closed out, a net change of +17 holders.
  • The largest PLx Pharma Inc. Common Stock buyer in Q3 2021 was Vanguard Group, an estimated $3.45M added.
  • The largest PLx Pharma Inc. Common Stock seller in Q3 2021 was Marshall Wace, an estimated $6.25M sold.

Based on aggregated 13F filings for Q3 2021.